Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.72 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13417680 | 0.98 | CHRM5 (0.70) | CHRM5CHRM3ALDH1A1NPC1POLB | |
| SCHEMBL18743787 | 0.96 | CHRM5 (0.72) | CHRM5CHRM3ALDH1A1NPC1POLB | |
| SCHEMBL23464917 | 0.93 | CHRM5 (0.75) | CHRM5CHRM3ALDH1A1NPC1POLB | |
| SCHEMBL2111226 | 0.87 | ALDH1A1 (0.67) | CHRM5CHRM3ALDH1A1NPC1POLB | |
| SCHEMBL2629206 | 0.86 | SIGMAR1 (0.66) | CHRM5CHRM3ALDH1A1NPC1POLB | |
| SCHEMBL18811886 | 0.86 | CHRM5 (0.66) | CHRM5CHRM3ALDH1A1NPC1POLB | |
| SCHEMBL18811738 | 0.86 | CHRM5 (0.66) | CHRM5CHRM3ALDH1A1NPC1POLB | |
| SCHEMBL20328825 | 0.86 | CHRM5 (0.66) | CHRM5CHRM3ALDH1A1NPC1POLB | |
| SCHEMBL23095532 | 0.85 | SIGMAR1 (0.74) | CHRM5CHRM3ALDH1A1NPC1POLB | |
| SCHEMBL24739915 | 0.84 | SIGMAR1 (0.55) | CHRM5CHRM3ALDH1A1NPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| US-20230258652-A1 | Phenacylbromide-Based Mass Tags For Carboxyl And Phenolic Functional Group Containing Analytes | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2023-08-17 | — | — | US | disclosed |
| US-20230258652-A1 | Phenacylbromide-Based Mass Tags For Carboxyl And Phenolic Functional Group Containing Analytes | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2023-08-17 | — | — | US | disclosed |
| US-20230242565-A1 | Macrolides with Modified Desosamine Sugars and Uses Thereof | ZIKANI THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230242565-A1 | Macrolides with Modified Desosamine Sugars and Uses Thereof | ZIKANI THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-06-22 | — | — | US | disclosed |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-06-22 | — | — | US | disclosed |
| US-9573895-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573895-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160107988-A1 | Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2016-04-21 | — | — | US | disclosed |
| US-20150352108-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON | ALZHEIMER'S INSTITUTE OF AMERICA (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150051111-A1 | ANALYSIS OF ESTRADIOL AND ANALYTES WITH PHENOLIC OH USING LABELING CHEMISTRY AND LC-MSMS WORKFLOW | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2015-02-19 | — | — | US | disclosed |
| US-20120238540-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 | MYREXIS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120238540-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 | MYREXIS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-8198458-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| WO-2011046970-A1 | AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON | MYREXIS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| US-6875765-B2 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160107988-A1 | Tetracycline Compounds | TREH, TUBB, TUBB6 | CHRM5 4760/4885CHRM3 4872/4885ALDH1A1 2506/4885 |
| US-20150352108-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON | TBK1, NFKBIA, CHUK | CHRM5 3147/4885CHRM3 3973/4885ALDH1A1 4754/4885 |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | PDXK, DTYMK, HIPK1 | CHRM5 4833/4885CHRM3 4544/4885ALDH1A1 3576/4885 |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | CHRM5 4860/4885CHRM3 4775/4885ALDH1A1 1798/4885 |
| US-20120238540-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 | TBK1, NFKBIA, IKBKB | CHRM5 4188/4885CHRM3 4507/4885ALDH1A1 4626/4885 |
| US-20230242565-A1 | Macrolides with Modified Desosamine Sugars and Uses Thereof | FUT6, DDOST, MGAM | CHRM5 2267/4885CHRM3 2910/4885ALDH1A1 4673/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | CHRM5 4859/4885CHRM3 4787/4885ALDH1A1 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.